Imeka
Imeka develops ANDI, an FDA-cleared AI-powered clinical software that analyzes brain white matter microstructure from MRI scans for diagnosis and monitoring of TBI, Alzheimer's disease, and multiple sclerosis. The platform serves clinical imaging centers across 40+ US states and pharmaceutical research partners.
- Company typePrivate
- Founded2011
- HeadquartersSherbrooke, Canada
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Imeka does
Imeka is a Canadian brain imaging technology company that develops ANDI (Advanced Neuro Diagnostic Imaging), an FDA 510(k)-cleared clinical software platform that combines Diffusion Tensor Imaging (DTI) with AI to analyze white matter microstructure from standard MRI scans. The platform performs automated segmentation of 33 fiber bundles, generates quantitative reports comparing each subject to age- and sex-matched controls drawn from a proprietary normative database of over 1,440 subjects, and supports longitudinal tracking. ANDI's measurement capabilities include free water imaging for neuroinflammation, myelin integrity assessment, and axonal integrity measurement, enabling detection of pathology in normal-appearing white matter across conditions such as traumatic brain injury, Alzheimer's disease, and multiple sclerosis. The technology runs on standard 1.5T or 3T MRI scanners from any manufacturer with a 5-8 minute acquisition sequence, and produces a fully automated cloud-based report.
Imeka operates two revenue streams: recurring clinical software licensing of ANDI to imaging centers and hospitals as a regulated medical device, and professional services to pharmaceutical companies for neuroimaging biomarker evaluation in clinical trials. ANDI is deployed across imaging centers in 40+ US states, distributed via direct field sales and through an OEM integration with GE Healthcare's BrainWave advanced diffusion processing application. The company markets primarily through medical conferences (RSNA, ASNR), peer-reviewed publications, and educational content, with a sales-led enterprise go-to-market motion targeting clinical imaging centers and pharmaceutical research partners.
Founded in 2011 by researchers from the Sherbrooke Connectivity Imaging Lab (SCIL), including co-founders Maxime Descoteaux (Chief Science Officer) and Pierre-Marc Jodoin, Imeka is headquartered in Sherbrooke, Quebec with a US regional office in Cambridge, Massachusetts. The company received its initial FDA 510(k) clearance for ANDI in July 2023 and an updated clearance for ANDI 2.0, adding brain volumetric analysis, in November 2025. Strategic partners include GE Healthcare (technology integration) and the Alzheimer's Drug Discovery Foundation (Alzheimer's biomarker development investment).
Imeka firmographics
Firmographics- Name
- Imeka
- Legal name
- IMEKA SOLUTIONS INC.
- Website
- https://imeka.ca
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Imeka develops ANDI, an FDA-cleared AI-powered clinical software that analyzes brain white matter microstructure from MRI scans for diagnosis and monitoring of TBI, Alzheimer's disease, and multiple sclerosis. The platform serves clinical imaging centers across 40+ US states and pharmaceutical research partners.
- Ownership category
- akta.pro rank
Imeka industry classification
Industry- Product category
- Neuroimaging Software
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
Keywords
Where Imeka is headquartered
LocationHeadquarters
- HQ city
- Sherbrooke
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
Imeka business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Clinical Software Licensing: ANDI clinical software is provided to imaging centers, hospitals, and clinics as a regulated medical device. Revenue generated through licensing of the FDA-cleared software for clinical use in patient diagnosis and monitoring.
- Pharmaceutical Research Services: Services to pharmaceutical companies for clinical trials and drug development research, including neuroimaging biomarker evaluation for neurological diseases such as Alzheimer's disease.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Clinical software licensing for imaging centers and hospitals |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Imeka product offering
Product offeringCore offering
Imeka develops and sells ANDI (Advanced Neuro Diagnostic Imaging), an FDA 510(k) cleared clinical software platform that combines Diffusion Tensor Imaging (DTI) with AI to analyze white matter microstructure in the brain from standard MRI scans. The cloud-based, fully automated platform performs segmentation of 33 fiber tracts, provides age- and sex-matched normative comparisons against a 1,440+ subject reference database, and generates comprehensive clinical reports for neurologists, radiologists, and pharmaceutical researchers.
Product overview
Imeka is a brain imaging technology company offering a unified clinical software platform centered on ANDI (Advanced Neuro Diagnostic Imaging). ANDI is an FDA 510(k)-cleared quantitative DTI analysis tool that processes MRI data to assess white matter microstructure. The product portfolio consists of the core ANDI platform, with ANDI 2.0 representing the latest major version that adds brain volumetry (macrostructure analysis) to its existing microstructure analysis capabilities. Both versions are cloud-based, fully automated, and designed for clinical use in neurology practices.
Differentiator
Problem solved
Functional benefit
Products and services
- ANDI (Advanced Neuro Diagnostic Imaging) FDA 510(k)-cleared clinical software that analyzes white matter microstructure using advanced diffusion tensor imaging (DTI). The proprietary, fully automated, and validated quantitative clinical software performs all steps required to create a streamlined report from raw MRI data, including automated segmentation of 33 fiber tracts and comparison to age- and sex-matched normative references. Designed for clinical imaging centers, hospitals, neurology and radiology practices.
- ANDI 2.0 Enhanced version of ANDI that adds brain volumetric analysis (macrostructure) to the existing white matter microstructure (DTI) analysis. Provides a comprehensive one-stop-shop solution for clinicians assessing brain health, with FDA 510(k) clearance.
Quantifiable outcome
- Data can be collected in as little as 5 minutes on a standard MRI machine
- +3 more outcomes
Companies that use Imeka
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Imeka technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability2 records
Feature8 records
Imeka partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- GE HealthcarecoreGE Healthcare integrated Imeka's non-invasive neuroimaging technology into the BrainWave advanced diffusion processing application. This integration allows researchers and clinicians to analyze diffusion MRI signals in the brain in greater detail, advancing precision medicine for brain health.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Imeka competitors and assessment
Company assessmentDirect peers
- RapidAI: RapidAI provides AI-driven imaging analysis across stroke and broader neurovascular conditions via Rapid MRI/CT platforms. Competes with Imeka in the AI neuroimaging category serving hospitals and clinical trial sponsors, albeit with stronger focus on acute stroke.
- SyntheticMR: SyntheticMR offers SyMRI (including SyMRI Diffusion) for quantitative brain tissue analysis and tissue segmentation from a single MRI scan. Comparable as an FDA-cleared quantitative DTI/brain-volumetry tool sold to clinical radiology and pharma research customers.
- Brainomix: Brainomix develops AI-based imaging biomarkers (e.g., e-Stroke suite) for stroke and vascular neurology, deployed across hospitals globally. Comparable as a regulated, imaging-AI clinical software vendor serving neurology practices and stroke centers.
- QMENTA: QMENTA is a cloud-based neuroimaging analysis platform specializing in DTI, white-matter analysis, and multi-site trial imaging management. Closely matches Imeka's cloud-hosted AI diffusion imaging and pharma biomarker services.
- Cortechs.ai: Cortechs.ai (formerly CorTechs Labs) markets NeuroQuant and LesionQuant, FDA-cleared quantitative MRI post-processing tools for brain volumetry and white-matter lesion analysis. Directly comparable to Imeka's ANDI as a regulated quantitative neuro-imaging software sold to imaging centers and used in MS, Alzheimer's, and TBI workflows.
- Blackford Analysis: Blackford Analysis provides an AI platform that curates and routes radiology AI applications, including neuroimaging algorithms, into clinical imaging workflows. Comparable as an enabler/channel partner for quantitative neurology imaging at imaging centers.
- Olea Medical: Olea Medical develops advanced MRI post-processing software (Olea Sphere) for diffusion, perfusion, and functional imaging used in stroke, MS, and oncology. Overlaps with Imeka's diffusion MRI and DTI analytics for neurological disease diagnosis and pharma research.
Emerging players
- Subtle Medical: Subtle Medical develops AI-based image enhancement tools (SubtleMR, SubtleGAD) for faster and higher-quality MRI. Adjacent to Imeka as an AI-for-MRI technology vendor pursuing OEM and clinical channels, with overlap in the pharma-services and clinical-trial imaging ecosystem.
Broad incumbents
- Viz.ai: Viz.ai is a well-funded imaging-AI company initially focused on stroke (Viz LVO) that has expanded into cardiology and other neurovascular workflows. Comparable as a high-growth regulatory-cleared imaging AI vendor targeting hospitals, though operating at larger scale and across more specialties than Imeka.
- Aidoc: Aidoc is a leading broad medical imaging AI platform with FDA-cleared modules across multiple anatomies, sold enterprise-wide to hospitals and imaging networks. Overlaps with Imeka in clinical radiology AI purchasing, but with a portfolio approach rather than white-matter specialization.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Imeka social profiles
Digital presenceImeka compliance and trust
Trust signalCompliance2 records
Imeka financial estimates
Financial estimateRevenue estimate
Valuation estimate
Imeka leadership team
Management profileNumber of profiles
Profiles5 records
Imeka funding detail
Funding detailFunding overview
Funding rounds4 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Imeka M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Imeka
What does Imeka do?
Imeka develops and sells ANDI (Advanced Neuro Diagnostic Imaging), an FDA 510(k) cleared clinical software platform that combines Diffusion Tensor Imaging (DTI) with AI to analyze white matter microstructure in the brain from standard MRI scans. The cloud-based, fully automated platform performs segmentation of 33 fiber tracts, provides age- and sex-matched normative comparisons against a 1,440+ subject reference database, and generates comprehensive clinical reports for neurologists, radiologists, and pharmaceutical researchers.
Is Imeka a public or private company?
Imeka is a private company. It is classified as venture growth investor backed and is currently operating.
When was Imeka founded?
Imeka was founded in 2011. It employs 11 to 50 people.
Where is Imeka based?
Imeka is headquartered in Sherbrooke, Canada, in the North America region.
How does Imeka make money?
Two revenue lines are on record. Clinical Software Licensing is the primary driver. The others are pharmaceutical Research Services.
Who are Imeka's main competitors?
Direct peers on record are RapidAI, SyntheticMR, Brainomix, QMENTA, Cortechs.ai, Blackford Analysis and Olea Medical. Subtle Medical is listed as an emerging player. Broad incumbents are Viz.ai and Aidoc.
Does Imeka have an API?
No public API is recorded for Imeka.
What industry is Imeka in?
Imeka's product category is Neuroimaging Software. Its primary akta.pro industry code is HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software, with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 334510 and its SIC code is 3841.